Several different mitochondrial DNA (mtDNA) sites for mutations of Leber’s hereditary optic neuropathy (LHON) have been reported to be present in patients with multiple sclerosis (MS). To further study this association of LHON and MS in the Korean population, we tested 20 MS patients for the presence of mtDNA mutations at nucleotide (nt) 11778 in all 20 patients, and at nt 14484, nt 3460 and nt 15257 in 15, 12 and 12 patients, respectively. However, none of the MS patients exhibited any pathogenic LHON mtDNA mutations. In conclusion, we found no evidence for any association between MS and the LHON mutation in the Korean population.

1.
Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ II, Nikoskelainen EK: Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 1988;242:1427–1430.
2.
Harding AE, Sweeney MG, Miller DH, Mumford CJ, Kellar-Wood H, Menard D, McDonald WI, Compston DA: Occurrence of a multiple sclerosis-like illness in women who have a Leber’s hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992;115:979–989.
3.
Nikoskelainen EK, Marttila RJ, Huoponen K, Juvonen V, Lamminen T, Sonninen P, Savontaus ML: Leber’s ‘plus’: Neurological abnormalities in patients with Leber’s hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 1995;59:160–164.
4.
Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, Da Costa J, Harding AE: The clinical features of Leber’s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 1995;118(pt 2):319–337.
5.
Bhatti MT, Newman NJ: A multiple sclerosis-like illness in a man harboring the mtDNA 14484 mutation. J Neuroophthalmol 1999;19:28–33.
6.
Kellar-Wood H, Robertson N, Govan GG, Compston DA, Harding AE: Leber’s hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Ann Neurol 1994;36:109–112.
7.
Vanopdenbosch L, Dubois B, D’Hooghe MB, Meire F, Carton H: Mitochondrial mutations of Leber’s hereditary optic neuropathy: A risk factor for multiple sclerosis. J Neurol 2000;247:535–543.
8.
Leuzzi V, Carducci C, Lenza M, Salvetti M, Ristori G, Di Giovanni S, Torroni A: LHON mutations in Italian patients affected by multiple sclerosis. Acta Neurol Scand 1997;96:145–148.
9.
Mojon DS, Herbert J, Sadiq SA, Miller JR, Madonna M, Hirano M: Lever’s hereditary optic neuropathy mitochondrial DNA mutations at nucleotides 11778 and 3460 in multiple sclerosis. Ophthalmologica 1999;213:171–175.
10.
Nishimura M, Obayashi H, Ohta M, Uchiyama T, Hao Q, Saida T: No association of the 11778 mitochondrial DNA mutation and multiple sclerosis in Japan. Neurology 1995;45:1333–1334.
11.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227–231.
12.
Kurtzke JF, Beebe GW, Norman JE Jr: Epidemiology of multiple sclerosis in US veterans. 1. Race, sex, and geographic distribution. Neurology 1979;29:1228–1235.
13.
Shibasaki H, McDonald WI, Kuroiwa Y: Racial modification of clinical picture of multiple sclerosis: Comparison between British and Japanese patients. J Hum Neurol Sci 1981;49:253–271.
14.
Kuroiwa Y, Igata A, Itahara K, Tsubaki T: Nationwide survey of multiple sclerosis in Japan: Clinical analysis of 1,084 cases. Neurology 1975;25:845–851.
15.
Choi MY, Hwang J-M: Optic neuritis associated with multiple sclerosis in Koreans. Neuroophthalmology 2000;23:75–82.
16.
Mashima Y, Yamada K, Wakakura M, Kigasawa K, Kudoh J, Shimizu N, Oguchi Y: Spectrum of pathogenic mitochondrial DNA mutations and clinical features in Japanese families with Leber’s hereditary optic neuropathy. Curr Eye Res 1998;17:403–408.
17.
Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding AE, Govan G, Bolhuis PA, Norby S: Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. Am J Hum Genet 1996;59:481–485.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.